Table 1. Clinico-pathological characteristics of patients with DLBCL (n=539).
| Overall (n=539) | Uric acid<Q3 (n=404) | Uric acid⩾Q3 (n=135) | P-value | |
|---|---|---|---|---|
|
Variable | ||||
| Gender | ||||
| Male | 275 (51.0%) | 192 (47.5%) | 83 (61.5%) | – |
| Female | 264 (49.0%) | 212 (52.5%) | 52 (38.5%) | 0.005 |
| BMI (kg m-2)a | 25.4 (23.2–28.1) | 24.9 (22.6–27.2) | 27.7 (24.8–30.8) | <0.0001 |
| Age at diagnosis (years) | 68 (59–77) | 67 (56–77) | 71 (63–79) | 0.001 |
| Serum creatinine (mg dl−1) | 0.9 (0.8–1.1) | 0.9 (0.8–1.0) | 1.1 (0.9–1.3) | <0.0001 |
| LDH (units) | 264 (197–431) | 259 (192–411) | 303 (208–507) | 0.027 |
| Location | ||||
| Graz | 335 (62.2%) | 242 (59.9%) | 93 (68.9%) | – |
| Salzburg | 203 (37.9%) | 162 (40.1%) | 42 (31.1%) | 0.062 |
|
Individual (R-)IPI and NCCN-IPI items> | ||||
| Age category | ||||
| ⩽40 years | 43 (8.0%) | 40 (9.9%) | 3 (2.2%) | – |
| 41–60 years | 109 (20.2%) | 90 (22.3%) | 19 (14.1%) | – |
| 61–75 years | 211 (39.2%) | 152 (37.6%) | 59 (43.7%) | – |
| >75 years | 176 (32.7%) | 122 (30.2%) | 54 (40.0%) | 0.002 |
| Site | ||||
| No extranodal disease | 298 (55.3%) | 229 (56.7%) | 69 (51.1%) | – |
| Extranodal disease | 241 (44.7%) | 175 (43.3%) | 66 (48.9%) | 0.260 |
| LDH ratio | ||||
| <ULN | 219 (40.6%) | 170 (42.1%) | 49 (36.3%) | – |
| 1–3 × ULN | 269 (49.9%) | 204 (50.5%) | 65 (48.2%) | – |
| >3 × ULN | 51 (9.5%) | 30 (7.4%) | 21 (15.6%) | 0.018 |
| Clinical stage (Ann Arbor) | ||||
| I&II | 278 (51.6%) | 207 (51.2%) | 71 (52.6%) | – |
| III&IV | 261 (48.4%) | 197 (48.8%) | 64 (47.4%) | 0.785 |
| ECOG PS | ||||
| 0–2 | 455 (84.4%) | 340 (84.2%) | 115 (85.2%) | – |
| ⩾2 | 84 (15.6%) | 64 (15.8%) | 20 (14.8%) | 0.776 |
|
Prognostic indices | ||||
| R-IPI | ||||
| Very good | 46 (8.5%) | 36 (8.9%) | 54 (40.0%) | – |
| Good | 296 (54.9%) | 225 (55.7%) | 71 (52.6%) | – |
| Poor | 197 (36.6%) | 143 (35.4%) | 54 (40.0%) | 0.597 |
| NCCN-IPI | ||||
| Low | 42 (7.8%) | 33 (8.2%) | 9 (6.7%) | – |
| Low intermediate | 198 (36.7%) | 159 (39.4%) | 39 (28.9%) | – |
| High intermediate | 218 (40.5%) | 155 (38.4%) | 63 (46.7%) | – |
| High | 81 (15.0%) | 57 (14.1%) | 24 (17.8%) | 0.115 |
Abbreviations: BMI=body mass index; DLBCL=diffuse large B-cell lymphoma; ECOG PS=Eastern Cooperative Oncology Group (ECOG) performance status (PS); LDH=lactate dehydrogenase; mg/dl=milligram per decilitre; NCCN-IPI=National Comprehensive cancer network international prognostic Index; R-IPI=revised international prognostic index; ULN=upper limit of normal.
BMI was only observed in a subset of the Graz cohort (n=235).
Continuous variables such as BMI are reported as medians (25–75th percentile), whereas count data are reported as absolute frequencies (percentages). Distribution overall and by uric acid level dichotomized at its 75th percentile (Q3, cut-off: 6.8 mg dl−1).
Q3: 75th percentile of the uric acid distribution.
P: P-value from a Wilcoxon's rank-sum test. Bold indicates P<0.05.